Ansa Biotechnologies
Ansa Biotechnologies, based in Emeryville, CA, specializes in enzyme-based DNA synthesis, focusing on sequences that are challenging to produce with existing methods. The company, part of the Y Combinator W20 batch, has raised $68 million in Series A financing to expand its innovative DNA synthesis technology.
Services
Ansa Biotechnologies offers a DNA synthesis service that aims to revolutionize the field of biological research and biotechnology. The service focuses on synthesizing complex sequences that are challenging or impossible to achieve with current methods. This includes sequences that are GC- or AT-rich, form secondary structures, or are repetitive. Ansa Biotechnologies employs an enzyme-based approach to make DNA synthesis faster, cleaner, and more accurate. Researchers can sign up for a free consultation and gain priority access to this service through the company's Early Access Program.
Company History
Ansa Biotechnologies was part of the Winter 2020 Y Combinator batch, marking its official entry into the startup ecosystem. Since its inception, the company has focused on innovating DNA synthesis techniques. It participated in the Global Synthetic Biology Conference, where it showcased its enzyme-based DNA synthesis technology. In a significant milestone, Ansa successfully synthesized and delivered challenging promoter sequences to its first Early Access customer, Enoda. The company recently raised $68 million in Series A financing to advance its technology platform, expand R&D and manufacturing facilities, and launch its DNA synthesis service.
Locations and Team
Ansa Biotechnologies is headquartered in Emeryville, California, USA. The company has a team of 72 employees who work both on-site and remotely. Ansa Biotechnologies operates primarily in the United States and extends its services to regions including America/Canada and partly remote locations. This diversified team plays a crucial role in developing and enhancing their groundbreaking DNA synthesis technology.
Industry Focus
Ansa Biotechnologies operates within the healthcare and industrial biotechnology sectors. The company's primary focus is on accelerating innovation in various fields such as therapeutics, diagnostics, and biomanufacturing by improving DNA synthesis methods. Their technology also has wide-ranging applications across pharmaceuticals, biological research, food and agriculture, and industrial biotechnology. By enabling the synthesis of complex DNA sequences, Ansa Biotechnologies aims to address significant challenges in these industries and foster advancements.
Funding and Financials
In a major financial milestone, Ansa Biotechnologies secured $68 million in Series A financing. This funding will be utilized to advance their technology platform, expand research and development, and increase manufacturing capabilities. The funds will also support the launch of their DNA synthesis service. This oversubscribed funding round highlights strong investor confidence in Ansa Biotechnologies' potential to transform the DNA synthesis market.